Dan Musat, Silviana Marineci, Mark V Sherrid
Index: Prog. Cardiovasc. Dis. 54(6) , 535-42, (2012)
Full Text: HTML
Pharmacologic therapy is the first line approach to relieve symptoms in obstructive hypertrophic cardiomyopathy. There are no randomized trials to evaluate their effect on prognosis. Gradient reduction by surgical septal myectomy is associated with excellent prognosis, but not all patients have symptoms severe enough to require surgery; and, guidelines recommend operation only for patients with high gradients and symptoms unresponsive to pharmacologic therapy. The combination of disopyramide and beta-blockade is effective in reducing resting gradients (though not to the extent of surgery). This review examines the question of whether pharmacologic reduction of gradient in asymptomatic patients or those with milder symptoms might decrease HCM-related mortality.Copyright © 2012 Elsevier Inc. All rights reserved.
| Structure | Name/CAS No. | Molecular Formula | Articles |
|---|---|---|---|
![]() |
Disopyramid phosphate
CAS:22059-60-5 |
C21H32N3O5P |
|
A review of the effects of disopyramide phosphate on left ve...
1987-02-01 [Angiology 38(2 Pt 2) , 174-83, (1987)] |
|
[Disopyramide phosphate: the electrophysiological mechanisms...
1985-05-01 [Kardiologiia 25(5) , 114-8, (1985)] |
|
Disopyramide-induced hypoglycemia in a non-diabetic hemodial...
2011-11-01 [Clin. Nephrol. 76(5) , 401-6, (2011)] |
|
A primer of disopyramide treatment of obstructive hypertroph...
2012-01-01 [Prog. Cardiovasc. Dis. 54(6) , 483-92, (2012)] |
|
Monitoring disopyramide, lidocaine, and quinidine by micella...
2011-01-01 [J. AOAC Int. 94(2) , 537-42, (2011)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved
